Currently, clinical trials investigating immunotherapy in breast cancer primarily focus on triple-negative subtypes, with discrepancy in efficacy among different stages, types of immunotherapy drugs, and PD-L1 status [42]; furthermore, the majority of these cases still do not benefit from immunotherapy [43]. This evidence concerns the gene CD274 and breast carcinoma.